Pluristem Therapeutics Inc. (NASDAQ:PSTI) Short Interest Down 23.7% in March

Pluristem Therapeutics Inc. (NASDAQ:PSTI – Get Rating) was the target of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 584,400 shares, a decrease of 23.7% from the March 15th total of 765,900 shares. Based on an average daily volume of 1,420,000 shares, the […]

Related Keywords

Zami Aberman ,Morgan Stanley ,Zacks Investment Research ,Nasdaq ,Capital Partners ,Investment Management ,Nia Impact Advisors ,Pluristem Therapeutics ,Pluristem Therapeutics Inc ,Get Rating ,Investment Research ,Director Zami Aberman ,Impact Advisors ,Capital Management ,Therapeutics Inc ,Nasdaq Psti ,Psti ,Medical ,Stocks ,Options ,Put ,Call ,